If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.


Mergers & Acquisitions

Business Roundup

March 1, 2019 | A version of this story appeared in Volume 97, Issue 9


SK Capital Partners, a private equity firm that specializes in chemicals, has raised $2.1 billion for a new fund. Current SK portfolio companies include SI Group, TPC Group, and Ascend Performance Materials.

Evonik Industries plans to add a line at its hydrogen peroxide plant in Antwerp, Belgium, increasing capacity there by 50%. The German firm is also in the process of acquiring the US hydro­gen peroxide producer PeroxyChem.

Nufarm has acquired Trunemco, a new seed treatment used to ward off hungry nematodes, from BASF. The treatment, which combines a microorganism and a biochemical, is expected to launch this year in the US.

S-Biomedic, a developer of microbiome-inspired bacterial treatments for therapeutic and cosmetic applications, has raised $4.6 million in series A funding from investors, including DSM. The start-up is a resident of Johnson & Johnson’s incubator in Belgium.

Saudi Aramco will buy a 9% stake in Zhejiang Petrochemical, which is building a crude-to-chemicals complex in Zhoushan, China. About half the 800,000 barrels per day of oil processed by the facility will be transformed into chemicals such as p-xylene and ethylene.

Anthos Therapeutics, a Cambridge, Massachusetts–based start-up, has launched with $250 million from the private equity firm Blackstone Life Sciences. Anthos licensed an antibody from Novartis that targets two blood-clotting proteins. It plans to test it in people with a high risk of developing cardiovascular disease.

Lonza will manufacture 2'-fucosyllactose, a humanmilk oligosaccharide, for DuPont Nutrition & Health. DuPont says HMOs are part of a larger microbiome investment strategy that includes scalable production methods.

Novartis has exercised an option to license AKCEA-APO(a)-LRx from Ionis Pharmaceuticals and its affiliate Akcea Therapeutics by paying a $150 million fee. The drug is an antisense compound being developed to treat cardiovascular disease.


This article has been sent to the following recipient:

Chemistry matters. Join us to get the news you need.